Risk Factors Update Summary
- Genentech assumed the development of GDC-1971, including combination therapies and commercialization.
- Added large-scale, pivotal clinical trials for product candidates RLY-4008, RLY-2608, and GDC-1971.
- Obtained orphan drug designation for lirafugratinib (RLY-4008) for cholangiocarcinoma treatment.
- Ongoing first-in-human clinical trials for RLY-4008, RLY-2608, and lirafugratinib.
- European Commission proposed reducing marketing exclusivity period for orphan medicines to nine years.
- Shifted focus from RLY-5836 to RLY-2608, impacting resource allocation and development priorities.
- Increased full-time employees from 323 to 327, anticipating significant future growth.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1812364&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.